Global T-Cell Lymphoma Market Size To Grow USD 3390.6 Million by 2030 | CAGR of 8.50%

Global T-Cell Lymphoma Market Size To Grow USD 3390.6 Million by 2030 

According to a research report published by Spherical Insights & Consulting, the Global T-Cell lymphoma market size to grow from USD 1,627.1 million in 2021 to USD 3,390.6 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.50% during the forecast period.  The T-Cell lymphoma market has grown due to the increasing number of the geriatric population and the risk of lymphoma due to autoimmune disorders. In addition, the change in lifestyle, increase in technological development, and the positive effect of the thymus (T)- cell lymphoma treatment is also driving the market growth.

Browse key industry insights spread across 222 pages with 112 market data tables and figures & charts from the report ”Global T-Cell Lymphoma Market Size, Share, and COVID-19 Impact Analysis, By Type of Lymphoma (Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, and Other Types of Lymphoma), By Type of Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Other Types of Therapies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030. ” in detail along with the table of contents. https://www.sphericalinsights.com/reports/t-cell-lymphoma-market

View a detailed Table of Content here–

The COVID-19 pandemic has made an adverse impact on credit portfolios. There has been an unprecedented rise in unemployment and disruption in economic activity, putting a strain on the solvency of customers and companies. Central banks have taken a proactive approach by injecting liquidity into the market by lowering interest rates and asset purchase programs. Managing and monitoring credit, market, liquidity, and operational risk across financial markets were hard enough with ongoing geopolitical tensions, international trade wars, and the occasional hurricanes and earthquakes. The current pandemic situation has forced chief risk officers and their teams to recalibrate old assumptions and models used to manage and monitor risk. COVID-19’s global impact has shown that interconnectedness plays an important role in international cooperation. As a result, many governments started rushing toward identifying, evaluating, and procuring reliable solutions powered by AI.

The peripheral T-cell lymphoma segment accounts for the largest market size during the forecast period

Based on the type of lymphoma, the global T-Cell lymphoma market is categorized into Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, and Other Types of Lymphoma. The peripheral T-cell lymphoma segment accounts for the largest market size during the forecast period. Peripheral T cell lymphoma, often known as PTCL, is a diverse category of lymphomas that accounts for between 5% and 15% of all cases of non-Hodgkin lymphoma in the world. In terms of their clinical presentation, these lymphomas are frequently aggressive.

The chemotherapy segment to hold a higher CAGR during the forecast period

Based on type of therapy, the T-Cell lymphoma market is categorized into Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Other Types of Therapies.  Chemotherapy is a drug treatment that is often used to treat lymphoma. It stops and slows the growth of cancer cells. In contrast to surgery and radiation therapy, chemotherapy can work on the whole body. These treatments can kill, or get rid of cancer cells in a certain part of the body.

North America is estimated to account for the highest market share in 2021.

The Global T-Cell lymphoma market has been segmented into five major regions: Asia-Pacific, Europe, APAC, Latin America, and MEA. North America is expected to be the largest market. Some things driving market growth in the North American region are the high number of cases of T-cell lymphoma, the presence of strong competitors, and more research and development. The GlobalCan 2020 report says that there were 8,506 new non-Hodgkin lymphoma cases in Canada, killing 313 people. Since T-cell lymphomas are a subtype of Non-Hodgkin lymphoma, the expected rise in Non-Hodgkin lymphoma cases will likely lead to an increase in the demand for different treatment options, which will help the market grow. Asia-Pacific to hold a higher CAGR during the forecast period.

Major global T-cell lymphoma vendors include Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., and Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation.

Some of the Key Developments:

• In September 2021, Soligenix Inc. announced that the Orphan Products Development had granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma.

• In December 2020, an investigational new drug application for LB1901 was approved by the Food and Drug Administration (FDA). LB1901 is a chimeric antigen receptor T-cell therapy that is being made to treat adults with T-cell lymphoma that has come back or doesn't respond to other treatments.

Market Segment

This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global T-Cell lymphoma market based on the below-mentioned segments:

Global T-Cell Lymphoma Market, By Type of Lymphoma

• Peripheral T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Anaplastic Large Cell Lymphoma
• Angio-immuno-blastic T-cell Lymphoma
• Other Types of Lymphoma

Global T-Cell Lymphoma Market, By Type of Therapy

• Radiotherapy
•  Chemotherapy
•  Immunotherapy
• Stem Cell Transplantation
• Other Types of Therapies

Global T-Cell Lymphoma Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa